Peel Hunt Maintains Brewin Dolphin Holdings PLC (LON:BRW) As “Buy”; Has Target Price per Share Of GBX 435.00; Infinity Pharmaceuticals, Inc. (INFI) Had 2 Bullish Analysts

Brewin Dolphin Holdings PLC (LON:BRW) Logo

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical has $17 highest and $1 lowest target. $6.50’s average target is 209.52% above currents $2.1 stock price. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Morgan Stanley upgraded the stock to “Overweight” rating in Monday, September 21 report. The rating was downgraded by Wells Fargo to “Market Perform” on Wednesday, June 15. Wells Fargo upgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Thursday, October 12 to “Outperform” rating. The rating was downgraded by JMP Securities on Tuesday, June 14 to “Market Perform”. Wedbush upgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Tuesday, June 14 to “Neutral” rating. The firm earned “Hold” rating on Monday, August 10 by Zacks. RBC Capital Markets maintained Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Friday, August 7. RBC Capital Markets has “Outperform” rating and $15 target. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Neutral” rating given on Thursday, February 25 by Wedbush. The rating was downgraded by Morgan Stanley on Wednesday, June 15 to “Equal-Weight”. See Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) latest ratings:

In an analyst note revealed on 16 May, Brewin Dolphin Holdings PLC (LON:BRW) stock “Buy” was reiterated by Analysts at Peel Hunt. They currently have a GBX 435.00 target price on the stock. Peel Hunt’s target price indicates a potential upside of 11.34% from the company’s last stock close price.

The stock increased 1.94% or $0.04 during the last trading session, reaching $2.1. About 428,390 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 38.35% since May 16, 2017 and is downtrending. It has underperformed by 49.90% the S&P500.

Another recent and important Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news was published by Seekingalpha.com which published an article titled: “Infinity Pharmaceuticals’ (INFI) CEO Adelene Perkins on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Since March 5, 2018, it had 1 insider purchase, and 1 insider sale for $2.96 million activity. $2.97 million worth of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) was bought by BVF PARTNERS L P/IL on Monday, April 9. Perkins Adelene Q had sold 5,000 shares worth $13,890 on Monday, March 5.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $117.75 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Investors sentiment increased to 0.62 in Q4 2017. Its up 0.15, from 0.47 in 2017Q3. It increased, as 11 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 12 funds opened positions while 9 raised stakes. 24.33 million shares or 10.88% less from 27.30 million shares in 2017Q3 were reported. Blackrock reported 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Tortoise Management Llc has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Royal Retail Bank Of Canada stated it has 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Renaissance Technologies Ltd Llc has 717,900 shares. National Bank & Trust Of America De has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Manufacturers Life Insurance The holds 0% or 2,628 shares in its portfolio. 16,250 are held by Savant Limited Liability. California-based Brandes Prns L P has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Mufg Americas Corp owns 452 shares for 0% of their portfolio. Geode Cap Management Limited Liability Corporation owns 325,567 shares. State Street holds 59,605 shares. The New York-based Morgan Stanley has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Moreover, Clear Harbor Asset Mngmt Limited Liability Corporation has 0.06% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Millennium Mgmt Ltd Liability has 1.20M shares. Platinum Invest Mngmt has invested 0.07% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Among 11 analysts covering Brewin Dolphin Holdings PLC (LON:BRW), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Brewin Dolphin Holdings PLC has GBX 481 highest and GBX 260 lowest target. GBX 376.36’s average target is -2.53% below currents GBX 386.13 stock price. Brewin Dolphin Holdings PLC had 119 analyst reports since July 29, 2015 according to SRatingsIntel. N+1 Singer maintained the stock with “Buy” rating in Tuesday, October 6 report. The stock has “Hold” rating by N+1 Singer on Wednesday, January 27. The firm has “Buy” rating given on Friday, December 4 by Liberum Capital. The stock of Brewin Dolphin Holdings PLC (LON:BRW) has “Overweight” rating given on Monday, September 25 by Barclays Capital. The company was upgraded on Wednesday, July 27 by Peel Hunt. The stock of Brewin Dolphin Holdings PLC (LON:BRW) has “Hold” rating given on Friday, December 4 by Numis Securities. On Wednesday, November 30 the stock rating was maintained by Cantor Fitzgerald with “Hold”. The firm has “Buy” rating given on Friday, May 26 by Shore Capital. RBC Capital Markets maintained the shares of BRW in report on Friday, January 8 with “Sector Perform” rating. The stock has “Hold” rating by Numis Securities on Wednesday, November 30.

Brewin Dolphin Holdings PLC, together with its subsidiaries, provides wealth management services in the United Kingdom, the Channel Islands, and the Republic of Ireland. The company has market cap of 1.06 billion GBP. It also offers investment management, financial planning, advisory, managed portfolio, and Brewin portfolio services, as well as custody, trade execution, and settlement services to private clients, charities, corporates, and intermediaries. It has a 24.13 P/E ratio.

The stock increased 1.40% or GBX 5.33 during the last trading session, reaching GBX 386.13. About 199,045 shares traded. Brewin Dolphin Holdings PLC (LON:BRW) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart